GlycoMimetics Inc (GLYC)
2.155
-0.12
(-5.48%)
USD |
NASDAQ |
Apr 18, 16:00
2.16
0.00 (0.00%)
After-Hours: 20:00
GlycoMimetics Cash from Operations (TTM): -34.88M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -34.88M |
September 30, 2023 | -35.18M |
June 30, 2023 | -35.11M |
March 31, 2023 | -44.37M |
December 31, 2022 | -46.46M |
September 30, 2022 | -51.35M |
June 30, 2022 | -59.68M |
March 31, 2022 | -57.06M |
December 31, 2021 | -57.49M |
September 30, 2021 | -54.37M |
June 30, 2021 | -48.93M |
March 31, 2021 | -49.87M |
December 31, 2020 | -39.24M |
September 30, 2020 | -42.35M |
June 30, 2020 | -44.29M |
March 31, 2020 | -41.14M |
December 31, 2019 | -51.98M |
September 30, 2019 | -49.17M |
June 30, 2019 | -45.81M |
March 31, 2019 | -47.47M |
December 31, 2018 | -43.33M |
Date | Value |
---|---|
September 30, 2018 | -41.72M |
June 30, 2018 | -37.87M |
March 31, 2018 | -30.92M |
December 31, 2017 | -29.77M |
September 30, 2017 | -27.35M |
June 30, 2017 | -28.60M |
March 31, 2017 | -29.56M |
December 31, 2016 | -29.73M |
September 30, 2016 | -30.73M |
June 30, 2016 | -9.698M |
March 31, 2016 | -8.766M |
December 31, 2015 | -8.242M |
September 30, 2015 | -7.439M |
June 30, 2015 | -25.76M |
March 31, 2015 | -10.40M |
December 31, 2014 | -4.282M |
September 30, 2014 | -3.693M |
June 30, 2014 | -2.328M |
March 31, 2014 | -14.25M |
December 31, 2013 | -15.54M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-59.68M
Minimum
Jun 2022
-34.88M
Maximum
Dec 2023
-46.77M
Average
-46.46M
Median
Dec 2022
Cash from Operations (TTM) Benchmarks
Altimmune Inc | -75.81M |
Cellectar Biosciences Inc | -32.38M |
PDS Biotechnology Corp | -33.64M |
Syros Pharmaceuticals Inc | -109.71M |
Precision BioSciences Inc | -84.11M |